 |
|
If you need to get a quote for any product, or have any questions, please fill in the
following contact form, we will contact you within 24 hours. If your have an account with us, click here to login to retrieve your information.
| Your Contact Information (Required *) |
| First Name* |
|
| Last Name* |
|
| E-Mail* |
|
| Company Name* |
|
| Address |
|
| City |
|
| State |
|
| Zip |
|
| Country |
|
| Phone |
|
| Fax |
|
| Web Site |
|
| |
| Products Interested (Browsing products) |
|
| Product ID |
CAS Number |
Product Name |
Quantity |
| A1-0325 |
625471-18-3 |
(S)-3-N-Boc-Aminopiperidine |
|
| A1-0346 |
3430-19-1 |
3-Amino-5-picoline |
|
| A1-1787 |
38410-80-9 |
Methyl (4S,5R)-2,2,5-trimethyl-1,3-dioxolane-4-carboxylate |
|
| A1-2293 |
30838-93-8 |
2-chloro-4,6-dimethyl-pyridine |
|
| A1-4250 |
20289-26-3 |
4-BENZYLOXY-1H-INDOLE |
|
| A1-6245 |
35386-24-4 |
1-(2-Methoxyphenyl)piperazine |
|
| JR02-H049 |
1051384-24-7 |
6-(trifluoromethyl)-spiro[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one,hydrochloride |
|
| JR6-L4374 |
181959-80-8 |
3-Pyrrolidinol, 1-(2-pyridinyl)-, (3R)- |
|
| JR6-L6354 |
1425107-70-5 |
Methanone, [(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl][4-(methylsulfinyl)-3,5-dinitrophenyl]- |
|
| JR6-L9279 |
1372561-57-3 |
Oxirane, 2-[(3Z)-5-cyclopropyl-3-penten-1-yl]-, (2R)- |
|
| JR6-L9339 |
21852-32-4 |
4-(Bromomethyl)-1,2-dimethoxybenzene |
|
| JR6-L9477 |
|
2,6-dibromo-4-ethylphenol |
|
| JR8-N0052 |
528-43-8 |
Magnolol |
|
| JR8-N0157 |
58546-55-7 |
Schizandrol B |
|
| JR8-N0342 |
39432-56-9 |
Eleutheroside E |
|
| JR8-N0425 |
60137-06-6 |
Curcurbitacin IIa |
|
| JR8-N0486 |
73069-28-0 |
Praeruptorin B |
|
| JR8-N0681 |
30462-34-1 |
Theaflavin-3-Gallate(TF-3-G) |
|
| JR8-N0767 |
152-95-4 |
Sophoricoside |
|
| JR8-N0795 |
99217-67-1 |
caesalpin J |
|
| JR8-N0822 |
2643-85-8 |
Oxypeucedaninhydrate |
|
| JR8-N0903 |
|
Emodin-1-O-ß-D-glucopyranoside |
|
| JR8-N1045 |
94-13-3 |
Propylparaben |
|
| JR8-N1233 |
183238-67-7 |
Nuezhenidic acid |
|
| JR8-N1279 |
27661-51-4 |
Leucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Comments |
| |
|
 |
|
|
|
|
|
|